Author

Juan Yuan

Karolinska Institutet

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Approach:experimental assay· 2 Organism:human· 2 Assay:ATAC-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Assay:ChIP-seq· 1 Research Focus:differential expression· 1

Frequent Co-Authors

Jonas MuhriD· 2 shared Eirini AntoniouiD· 1 shared Eltjona RrapajiD· 1 shared Guido BaselliiD· 1 shared Henrik LindehelliD· 1 shared Idha KurtsdotteriD· 1 shared Ilknur Safak Demirel· 1 shared Iria Laura MartineziD· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Jonas MuhrORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

SOX21 Suppresses Glioblastoma Growth by Repressing AP-1 Activity

Eltjona Rrapaj, Juan Yuan, Idha Kurtsdotter, Vsevolod Andreevich Misyurin, Guido Baselli, Johan Holmberg, Oscar Persson, Maria Bergsland, Jonas Muhr

This study shows SOX21 suppresses glioblastoma stem cells by repressing AP-1 activity, leading to reduced tumor growth and improved survival in mouse models.

Cell Death and Disease · Jan 31, 2026Peer-reviewedCancer Biology

HIF2α negatively regulates MYCN protein levels and promotes a low-risk noradrenergic phenotype in neuroblastoma.

Juan Yuan, Subhamita Maitra, Eirini Antoniou, Jiacheng Zhu, Wenyu Li, Ilknur Safak Demirel, Kostantinos Toskas, Iria Laura Martinez, Lacin Ozcimen, Henrik Lindehell, Jonas Muhr, Jakob J. E. Stenman, Per Kogner, Oscar C. Bedoya-Reina, Susanne Schlisio, Johan Holmberg

This paper shows that HIF2α reduces MYCN protein levels and promotes a low-risk noradrenergic phenotype in neuroblastoma, suggesting HIF2 has tumor suppressor rather than oncogenic function.

Proceedings of the National Academy of Sciences · Oct 21, 2025Peer-reviewedCancer Biology